Cost-Effectiveness of Strategies for Treatment Timing for Perinatally Acquired Hepatitis C Virus.

ABSTRACT:

Importance

Prevalence of chronic hepatitis C virus (HCV) infection among pregnant people is increasing in the US. HCV is transmitted vertically in 7% to 8% of births. Direct-acting antiviral (DAA) therapy was recently approved for children with HCV who are 3 years or older. The clinical and economic impacts of early DAA therapy for young children with HCV, compared with treating at older ages, are unknown.

Objective

To develop a state-transition model to project clinical and economic outcomes for children with perinatally acquired HCV to investigate the cost-effectiveness of treating at various ages.

Design, setting, and participants

The study team modeled the natural history of perinatally acquired HCV to simulate disease progression and costs of a simulated a cohort

SUBMITTER: Curtis MR 

PROVIDER: S-EPMC10928541 | biostudies-literature | 2024 May

REPOSITORIES: biostudies-literature